AR017079A1 - Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso. - Google Patents

Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.

Info

Publication number
AR017079A1
AR017079A1 ARP980104487A ARP980104487A AR017079A1 AR 017079 A1 AR017079 A1 AR 017079A1 AR P980104487 A ARP980104487 A AR P980104487A AR P980104487 A ARP980104487 A AR P980104487A AR 017079 A1 AR017079 A1 AR 017079A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
procedure
same
treatment method
Prior art date
Application number
ARP980104487A
Other languages
English (en)
Original Assignee
West Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Christopher filed Critical West Christopher
Publication of AR017079A1 publication Critical patent/AR017079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica, un proceso para la preparacion de la misma, un método de tratamiento y su uso, donde dicha composicion farmacéutica comprendemicropartículas poliméricas que incluyen una droga, preferentemente olanzapina, y un ácido graso, cuya composicion puede ser adaptada para proveer unavelocidad de liberacion de droga que es aproximadamente lineal en el tiempo, y que tiene un efecto de liberacion repentina o explosiva insignificante.
ARP980104487A 1997-09-09 1998-09-09 Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso. AR017079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system

Publications (1)

Publication Number Publication Date
AR017079A1 true AR017079A1 (es) 2001-08-22

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104487A AR017079A1 (es) 1997-09-09 1998-09-09 Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.

Country Status (10)

Country Link
EP (1) EP1011680A2 (es)
JP (1) JP2001515862A (es)
AR (1) AR017079A1 (es)
AU (1) AU745511B2 (es)
CA (1) CA2302762A1 (es)
GB (1) GB9718986D0 (es)
NO (1) NO20001219L (es)
NZ (1) NZ502710A (es)
WO (1) WO1999012549A2 (es)
ZA (1) ZA987762B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
ES2605402T3 (es) 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
MXPA06011924A (es) 2004-04-15 2007-06-11 Alkermes Inc Dispositivo de liberacion continua base polimeros.
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
MX2009003735A (es) * 2006-10-05 2009-04-22 Panacea Biotec Ltd Composicion en deposito inyectable y su procedimiento de preparacion.
GEP20125597B (en) 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
ES2661037T3 (es) 2007-07-31 2018-03-27 Otsuka Pharmaceutical Co., Ltd. Procedimientos para producir una suspensión de aripiprazol y una formulación liofilizada
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
ES2572948T3 (es) * 2010-11-25 2016-06-03 Shan Dong Luye Pharmaceutical Co., Ltd. Composiciones de rotigotina o sales farmacéuticamente aceptables de rotigotina
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR102045721B1 (ko) * 2019-03-27 2019-11-18 주식회사 씨트리 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
AU8992598A (en) 1999-03-29
CA2302762A1 (en) 1999-03-18
WO1999012549A3 (en) 1999-05-06
JP2001515862A (ja) 2001-09-25
WO1999012549A2 (en) 1999-03-18
NO20001219D0 (no) 2000-03-09
GB9718986D0 (en) 1997-11-12
EP1011680A2 (en) 2000-06-28
NZ502710A (en) 2001-09-28
NO20001219L (no) 2000-03-09
ZA987762B (en) 2000-02-28
AU745511B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AR017079A1 (es) Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
MX9203116A (es) Articulo compuesto que comprende microestructuras orientadas y metodo para su fabricacion.
ES2177022T3 (es) Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo.
MX9201782A (es) Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
DE59601880D1 (de) Verfahren zur herstellung hydrophiler oder teilweise hydrophiler, anorganischer aerogele
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
DK647789D0 (da) Kosmetisk eller farmaceutisk komposition indeholdende mikrosfaerer af polymere eller af fedtstofferforsynet med mindst et aktivt produkt
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
EE04540B1 (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks ja mikroosakeste kasutamine
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
ES2113095T3 (es) Preparacion solida de liberacion rapida, su produccion y su uso.
ES2137372T3 (es) Solucion antifungica para las uñas.
ES2141208T3 (es) Utilizacion de una cantidad eficaz de sustancias activas para el tratamiento de pieles mixtas.
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ES2103369T3 (es) Derivados de lanolina como sustancias que aceleran la penetracion y su aplicacion en sustancias farmaceuticas u otras formulaciones que contienen sustancias biologicamente activas.
FI972949A0 (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
MX9304185A (es) Producto y composicion farmaceutica que lo contiene para el tratamiento de la mastitis y la mestritis bovina.